Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Shares Outstanding readings, the most recent being $18.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 76.78% to $18.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 million, a 76.78% increase, with the full-year FY2025 number at $18.5 million, up 76.78% from a year prior.
  • Shares Outstanding hit $18.5 million in Q4 2025 for Avalo Therapeutics, up from $17.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $18.5 million in Q4 2025 to a low of $39164.0 in Q4 2021.
  • Median Shares Outstanding over the past 5 years was $8.0 million (2021), compared with a mean of $6.6 million.
  • The widest YoY moves for Shares Outstanding: up 1940.38% in 2023, down 99.41% in 2023.
  • Avalo Therapeutics' Shares Outstanding stood at $39164.0 in 2021, then increased by 0.33% to $39294.0 in 2022, then skyrocketed by 1940.38% to $801746.0 in 2023, then surged by 1206.14% to $10.5 million in 2024, then soared by 76.78% to $18.5 million in 2025.
  • The last three reported values for Shares Outstanding were $18.5 million (Q4 2025), $17.8 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.